Limitations of Risperidone in Treatment-Resistant Obsessive-Compulsive Disorder

Efficacy and Response

Approximately 33% of patients with SSRI-resistant obsessive-compulsive disorder show a clinically significant response to antipsychotic augmentation, meaning two out of three patients will not respond adequately, according to the American College of Neuropsychopharmacology 1
The effect of risperidone augmentation has a smaller effect size compared to initial SSRI treatment, highlighting the limited therapeutic gain, as reported by the National Institute of Mental Health 1
The addition of cognitive behavioral therapy with exposure and response prevention has larger effect sizes than antipsychotic augmentation alone, making risperidone a suboptimal choice when cognitive behavioral therapy is available, as recommended by the American Psychiatric Association 2, 3

Weight gain and metabolic dysregulation are primary concerns that require ongoing monitoring of weight, blood glucose, and lipid profiles, according to the Endocrine Society 1, 2, 3
These metabolic effects can lead to long-term complications such as type 2 diabetes mellitus and cardiovascular disease, particularly problematic with a 10-year treatment history, as reported by the American Heart Association 1

N-acetylcysteine has the strongest evidence among glutamatergic agents, with three out of five randomized controlled trials showing superiority to placebo, with a more favorable side effect profile, as reported by the National Institute of Mental Health 1, 2
Memantine has shown efficacy in multiple trials and can be considered with fewer metabolic concerns, according to the American Academy of Neurology 1, 2
Deep rTMS is FDA-approved for treatment-resistant obsessive-compulsive disorder with a moderate therapeutic effect (effect size = 0.65) and a 3-fold increased chance of treatment response compared to sham, without systemic side effects, as recommended by the American Psychiatric Association 2

Do not combine risperidone with clomipramine without careful monitoring due to increased risk of severe side effects, as warned by the FDA 1
Monitor for signs of serotonergic syndrome when combining serotonergic medications: agitation, confusion, rapid heart rate, dilated pupils, muscle stiffness, or hyperthermia, as recommended by the American Association of Poison Control Centers 2, 3
In patients with cardiac conditions, seizure history, or elderly, start with lower doses and titrate gradually, as recommended by the American Geriatrics Society 4